BioAge Labs Inc. is set to raise up to $157.5 million in its IPO, offering 7.5 million shares priced between $17 and $19, aiming to address obesity and metabolic disease.
The company will achieve a market value of approximately $587 million at the top of its IPO price range, showcasing its growth and potential within the biotech sector.
Notable shareholders include CEO Kristen Fortney with 9.8%, and firms like Andreessen Horowitz and Khosla Ventures, reflecting strong backing from reputable investors.
The IPO, led by established banks including Goldman Sachs and Morgan Stanley, highlights BioAge's ambition to become a significant player on the Nasdaq Global Market with the symbol BIOA.
[
Collection
]
[
|
...
]